Convert between INJ and US dollars at the live rate.
$52.62
−90.68% from current
$0.657401
+645.36% from current
Independent editorial ranking. Score is 0–10 across six criteria: Security, Fees, UX, Features, Support, Reputation.
US and EU users who prioritise a spotless security record — no major hack since 2011 — and want a serious pro-grade trading terminal.
Institutions and funds requiring an SEC-registered venue with segregated qualified custody and audited on-chain reserves.
Active spot traders chasing the deepest global liquidity and the widest listing catalogue outside the US perimeter.
Traders who mix spot and on-chain — the Web3 wallet, DEX aggregator and Ethereum L2 X Layer sit inside the same account as CEX pairs.
Long-horizon EU holders who want the oldest continuously-operating exchange (2011) with conservative listings and full MiCA licensing.
Derivatives-first traders who want tighter perp funding and a maker-friendly fee schedule; accept offshore regulatory footprint.
Top coins in the same category, ordered by market cap.
Injective (INJ) is a Cosmos-based Layer-1 blockchain optimised for decentralised finance, particularly derivatives trading. Launched in 2020 by Injective Labs (co-founded by Eric Chen and Albert Chon), Injective was one of the first Cosmos-ecosystem chains to focus specifically on financial applications with a native on-chain orderbook, cross-chain interoperability via IBC (Inter-Blockchain Communication), and Ethereum-compatible smart contracts.
In 2026, Injective sits in the top-40 cryptocurrencies by market capitalisation. Its positioning is closest to a hybrid of Cosmos technology (IBC interoperability, Tendermint consensus, appchain sovereignty) with EVM compatibility (via the inEVM subnet launched in 2024) and specialised trading infrastructure (native central-limit orderbook, MEV auction mechanism).
INJ's tokenomics have been distinctive: a substantial share of protocol fee revenue is burned via weekly buyback-and-burn auctions, producing genuine deflationary pressure that scales with network activity. This has made INJ one of the few crypto assets with a clear, mechanical, price-independent supply-reduction mechanism.
Injective runs on Tendermint BFT consensus with approximately 60 active validators. Block times are approximately 1 second with instant finality. The chain's core capabilities include:
The chain's design specifically targets financial applications: high-frequency trading, derivatives, RWA tokenisation, structured products. Consumer application activity is meaningful but secondary to Injective's DeFi focus.
INJ has a soft maximum supply target of 100 million tokens, though the current design uses dynamic emissions calibrated to network activity. As of July 2026, approximately 98-100 million INJ are in circulation.
The distinguishing INJ mechanism is the weekly burn auction. Every week, 60% of protocol fees (from dApps deployed on Injective) are auctioned off to a permissionless bidding process; the winning bidder receives the fees in various tokens, and the INJ they bid is burned. This is one of the most direct fee-to-burn mechanisms in crypto.
Cumulative INJ burned to date sits in the tens of millions — a meaningful percentage of total supply. Burn rate scales directly with dApp fee revenue on Injective, so as ecosystem activity grows, burn rate grows.
INJ staking to validators produces approximately 8-12% APR gross. Combined with the burn mechanism's deflationary pressure, real INJ economics can be significantly better than nominal yield suggests during active network periods.
Injective's IBC connectivity is a strategic asset. Assets can move between Injective and other Cosmos chains without bridges, and traders can move seamlessly between Osmosis (spot), Injective (derivatives), and Neutron (structured products) using the same infrastructure.
Injective's 2026 setup is defined by three variables: whether the burn mechanism continues to produce meaningful supply reduction as ecosystem activity grows, whether Cosmos-ecosystem DeFi captures meaningful share against Ethereum L2s and Solana, and whether inEVM attracts genuine third-party developer traction.
The bull case is decisive Cosmos DeFi growth combined with Injective as the leading derivatives chain in that ecosystem. The bear case is that Ethereum L2s and Solana continue to capture the vast majority of DeFi and derivatives activity, leaving Injective as a niche but functional chain.
Analysis last updated:
Injective (INJ) trades at $4.90 with a 24-hour volume of $45.18M and a market capitalization of $490.48M. The asset is currently ranked #101 among all tracked cryptocurrencies.
In the last 24 hours, the INJ price has fallen +6.06%. On a seven-day window, Injective has retraced +3.21%, under sustained selling pressure on both windows. Short-term moves are often amplified by liquidity, news flow, and derivatives positioning, so confirm signals across multiple indicators before acting.
Injective's all-time high of $52.62 was set on March 14, 2024. The current price sits +90.68% below that peak. Distance from the all-time high is a common reference point when evaluating long recoveries and macro support or resistance.
Buying Injective (INJ) is a five-step routine once you have picked the right venue and pair. The steps below mirror what most investors do today.
You can also use the Injective converter above to estimate how much INJ you would get for a given dollar amount before placing the order.
Whether Injective is a good investment depends on your goals, time horizon, and tolerance for volatility. Like all cryptocurrencies, INJ carries real market risk: prices can rise or fall sharply in a day, and past performance is not a reliable indicator of future returns.
This page provides data and analysis for educational purposes only. It is not financial advice. Always do your own research, diversify, and never invest more than you can afford to lose.
